PRODUCT INFORMATION

# OXYCOMPLEX NS

***Oxytetracycline 100mg/ml as Oxytetracycline Hydrochloirde***
***Flunixin 20mg/ml as Flunixin Meglumine***

## INDICATIONS

For the control and treatment of infectious diseases of cattle caused by or associated with organisms sensitive to oxytetracycline, where concurrent analgesic, anti-inflammatory, anti-endotoxic or antipyretic therapy is desired.

The product is especially indicated for the treatment of respiratory disease (particularly that associated with *Mannheimia* and *Pasteurella* infection) and acute mastitis (in conjunction with appropriate intramammary therapy).


## BENEFITS

- A powerful combination product with a proven antibiotic and a potent anti inflammatory agent
- Broad spectrum activity against Gram-negative and Gram-positive bacteria
- Rapid response and dramatic results
- For treatment of pneumonia,mastitis, metritis & gastroenteritis
- For intravenous & intramuscular use
- Excellent syringeability

## PACKAGING

| LIST NO. | UNIT PACKAGE | CASE SIZE |
|---|---|---|
| 1OXY004 | 100ml | 12 |

See reverse side for Administration and Dosage.

Bimeda®
Broomhill Road
Tallaght
Dublin 24, Ireland
Tel: 1850-515253 Fax: 01 451 5803

www.bimeda.ie

TECHNICAL INFORMATION

# OXYCOMPLEX NS

## *Oxytetracycline hydrochloride*
## *Flunixin Meglumine*

### PRESENTATION
A clear yellow to amber aqueous solution for injection. Each ml contains 100mg Oxyteracycline (as oxytetracycline hydrochloride) and 20mg Flunixin ( as flunixin meglumine)

### TARGET SPECIES
Cattle.

### INDICATIONS FOR USE
For the control and treatment of infectious diseases of cattle caused by or associated with organisms sensitive to oxytetracycline, where concurrent analgesic, anti-inflammatory, anti-endotoxic or antipyretic therapy is desired.
The product is especially indicated for the treatment of respiratory disease (particularly that associated with Mannheimia and Pasteurella infection) and acute mastitis (in conjunction with appropriate intramammary therapy)

### CONTRAINDICATIONS
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product.

### SPECIAL WARNINGS FOR EACH TARGET SPECIES
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Rapid intraveneous injection in cattle may occasionally cause cardiovascular collapse.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a potential risk of renal toxicity. It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.
Concurrent administration of methoxyflurane anaesthesia or other potentially nephrotoxic drugs should be avoided.

### SPECIAL PRECAUTIONS FOR USE
i. Special precautions for use in animals
Do not exceed the stated dose or duration of treatment.
ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals
Avoid eye contact and direct contact with skin. To avoid possible sensitisation reactions, avoid contact with skin. Gloves should be worn during application.
Wash hands after use.
In case of accidental contact with eyes, rinse immediately with plenty of water and seek medical advice.
The product may cause reactions in sensitive individuals. If you have known hypersensitivity for non-steroidal anti-inflammatory products, do not handle the product. Reactions may be serious.
Avoid accidental self-injection.

### ADVERSE REACTIONS
Prolonged use of NSAIDs, including flunixin, may predispose or lead to gastrointestinal ulceration.

### USE DURING PREGNANCY, LACTATION OR LAY
Reports of teratogenicity, effects on breeding performance, or gestation lengths have not been noted following use of flunixin.
Use with care in pregnant animals.
The use of tetracyclines during the period of tooth development, including late pregnancy, may lead to tooth discolouration.

### INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS
The product may potentiate the effects of Warfarin and related drugs.
Because of their common mode of action, flunixin may potentiate and be potentiated by other NSAIDs which act by interfering with prostaglandin synthesis.

### AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
1 ml per 10 kg bodyweight (equivalent to 10 mg oxytetracycline and 2 mg flunixin per kg bodyweight) daily for up to 5 days.
The first injection should be administered intravenously, slowly, with subsequent injections given intramuscularly.
Do not inject more than 20 ml intramuscularly at a single site. Where the dose exceeds 20 ml it should be divided between two or more sites, as appropriate.

### OVERDOSE
Overdosing by intramuscular injection may give rise to swellings at the site of injection. Treatment should be symptomatic.

### WITHDRAWAL PERIODS
Meat: Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 31 days following the last treatment.
Milk: Do not use in cattle producing milk for human consumption.

### INCOMPATIBILITIES
None.

### SHELF LIFE
(a) Shelf-Life – of the veterinary medicinal product as packaged for sale: 2 years
(b) Shelf-Life – after first opening the immediate packaging: 28 days

### SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 25°C. Protect from light.
Following withdrawal of the first dose, use the product within 28 days. Discard unused material.

### SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED MEDICINAL PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

### MARKETING AUTHORISATION HOLDER
Cross Vetpharm Group Limited, Broomhill Road, Tallaght,
Dublin 24, Ireland

### MARKETING AUTHORISATION NUMBER
VPA 10126/063/001

### LEGAL CATEGORY
POM-V

### PACKAGE QUANTITIES
100ML MULTIDOSE VIALS

A full product SPC is available on request from Bimeda or alternatively can be found on the VMD website